Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes

Sponsor
Radicle Science (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05837910
Collaborator
(none)
1,200
1
4
6.1
196.4

Study Details

Study Description

Brief Summary

A randomized, blinded, placebo-controlled study assessing the impact of health and wellness products on feeling of anxiety, stress, and other health outcomes

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Calm Active Study Product 1.1 Usage
  • Dietary Supplement: Calm Active Study Product 1.2 Usage
  • Dietary Supplement: Calm Active Study Product 1.3 Usage
  • Dietary Supplement: Placebo Control Form 1
N/A

Detailed Description

This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for less anxiety or stress, (2) indicate an interest in taking a health and wellness product to potentially help their feelings of anxiety or stress, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be stratified based on gender at birth then randomized to one of the study armsParticipants will be stratified based on gender at birth then randomized to one of the study arms
Masking:
Single (Participant)
Masking Description:
Participants will be blinded to the product they receive.
Primary Purpose:
Other
Official Title:
Radicleâ„¢ Calm 2: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Other Health Outcomes
Actual Study Start Date :
Apr 3, 2023
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Oct 6, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo Control 1

Calm Product Form 1 - control

Dietary Supplement: Placebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Experimental: Active Product 1.1

Calm Product Form 1 - active product 1

Dietary Supplement: Calm Active Study Product 1.1 Usage
Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.

Experimental: Active Product 1.2

Calm Product Form 1 - active product 2

Dietary Supplement: Calm Active Study Product 1.2 Usage
Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.

Experimental: Active Product 1.3

Calm Product Form 1 - active product 3

Dietary Supplement: Calm Active Study Product 1.3 Usage
Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.

Outcome Measures

Primary Outcome Measures

  1. Change in feelings of anxiety [6 weeks]

    Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety)

Secondary Outcome Measures

  1. Change in stress [6 weeks]

    Mean difference in stress score as assessed by National Institutes of Health (NIH) Toolbox Perceived Stress Survey (scale 10-50; where lower scores correspond to less stress)

  2. Change in cognitive function [6 weeks]

    Mean difference in cognitive function score as assessed by PROMIS Cognition Function 4A (scale 4-20; where lower scores correspond to poorer cognitive function)

  3. Change in sleep [6 weeks]

    Mean difference in sleep score as assessed by PROMIS Sleep Disturbance 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance)

  4. Change in mood (emotional distress) [6 weeks]

    Mean difference in mood score as assessed by PROMIS Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress)

  5. Change in libido [6 weeks]

    Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 2-10; where lower scores correspond to less interest in sexual activity)

  6. Minimal clinically important difference (MCID) in feelings of anxiety [6 weeks]

    Likelihood of achieving a MCID in sleep disturbance, as measured by PROMIS Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety)

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities

  • Resides in the United States

  • Endorses fewer feelings of anxiety or stress as a primary desire

  • Selects feelings of anxiety or stress, looking to improve their feelings of anxiety or stress, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product

  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion Criteria:
  • Reports being pregnant, trying to become pregnant, or breastfeeding

  • Unable to provide a valid US shipping address

  • The calculated validated health survey (PRO) measurement result is less than mild severity/impairment

  • Reports a diagnosis of liver or kidney disease

  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)

  • Unable to read and understand English

  • Reports current enrollment in a clinical trial

  • Lack of reliable daily access to the internet

  • Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection

  • Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied: anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs (monoamine oxidase inhibitors)

  • Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radicle Science, Inc Del Mar California United States 92014

Sponsors and Collaborators

  • Radicle Science

Investigators

  • Principal Investigator: Emily K. Pauli, PharmD, Radicle Science, Inc

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Radicle Science
ClinicalTrials.gov Identifier:
NCT05837910
Other Study ID Numbers:
  • RADX-2302
First Posted:
May 1, 2023
Last Update Posted:
May 1, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 1, 2023